Please login to the form below

Not currently logged in
Email:
Password:

kidney disease

This page shows the latest kidney disease news and features for those working in and with pharma, biotech and healthcare.

Astellas files new application for expanded use of roxadustat in Japan

Astellas files new application for expanded use of roxadustat in Japan

Astellas has set its sights on extending the use of roxadustat into Japan, for the treatment of anaemia associated with chronic kidney disease (CKD) in non-dialysis patients. . ... The standard treatment used to treat anaemia in people with chronic

Latest news

More from news
Approximately 20 fully matching, plus 137 partially matching documents found.

Latest Intelligence

  • Case study: What we're made of Case study: What we're made of

    If we don’t drink enough water, it can lead to headaches, constipation, tiredness and more serious problems, such as urinary infections and kidney disease. ... This could be a side effect of a condition such as stroke, motor neurone disease, multiple

  • 25 Women Leaders in UK Healthcare 25 Women Leaders in UK Healthcare

    The firm has just signed a long-term collaboration with AZ for the discovery of new drugs for chronic kidney disease and idiopathic pulmonary fibrosis (IPF). ... disease and applying machine learning, artificial intelligence and collapsing analysis to

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    of JAK proteins is an established method of controlling the symptoms of this disease. ... The sales forecast for Zolgensma is $2.09bn. Roxadustat, from AstraZeneca, FibroGen and Astellas, targets anaemia in chronic kidney disease (CKD).

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    FibroGen in China for patients with anaemia in chronic kidney disease. ... AstraZeneca’s goal is to realise complete disease management, covering prevention, screening, diagnosis, treatment and follow- up.

  • The invisible army The invisible army

    Studies with COPD and chronic kidney disease patients indicate that carers can have a positive influence on patient adherence to medication and healthy behaviours, thus driving positive outcomes in the process.

More from intelligence
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Its Know Your Numbers week Its Know Your Numbers week

    One in 4 adults in the UK has high blood pressure so the risk of developing heart disease, heart attacks, strokes, kidney disease and vascular dementia are very real. ... Lack of exercise. Being overweight. Chronic Kidney Disease. Regularly drinking

  • What are you doing, Dave?

    parents. Google's DeepMind is exploring the use of AI in managing head and neck cancer, acute kidney injury, and detection of eye disease. ... The IBM Watson supercomputer is also being used to help manage cancer, as well as analysing data on genes,

  • Lighthouse Medical Communications US makes the list of finalists for the 2018 PM360 Trailblalzer Awards

    This exciting news is a true testament to the American Kidney Fund’s commitment to improving the lives of patients with chronic kidney disease.  ACT on Anemia was one of a ... ACT on Anemia - Anemia in Chronic Kidney Disease, is a multi-channel

  • Making good practice common practice in rare disease

    However, fatigue scores can’t be explained purely by disease activity and depression. ... 2015 - 88% of people with early-stage autosomal dominant polycystic kidney disease (ADPKD), reported physical symptoms including pain and general malaise.

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics